Trastuzumab in Treating Patients With Stage III, Stage IV, or Recurrent Endometrial Cancer

Inclusion Criteria: * Histologically confirmed endometrial adenocarcinoma * Advanced, recurrent, or persistent disease * Refractory to curative therapy * HER2/neu gene amplification by fluorescent in situ hybridization * Measurable disease * Previously irradiated field as sole site of measurable disease allowed if evidence of progression since completion of radiotherapy * Performance status - GOG 0-2 * Absolute neutrophil count ? 1,500/mm\^3 * Platelet count ? 100,000/mm\^3 * Bilirubin ? 1.5 times upper limit of normal (ULN) * Creatinine ? 1.5 times ULN * LVEF ? 45% by echocardiogram or MUGA * History of coronary artery disease and/or congestive heart failure allowed if medical management of condition has been stable within the past 6 months * No active or unstable cardiac disease * No active angina * No myocardial infarction within the past 6 months * No requirement for supplemental oxygen at rest or with ambulation * Not pregnant or nursing * Negative pregnancy test * Fertile patients must use effective contraception * No active infection requiring antibiotics * No uncontrolled infection * No other invasive malignancy within the past 5 years except nonmelanoma skin cancer * No other unstable medical condition that would preclude study participation * At least 3 weeks since prior biologic and immunologic agents directed at the malignant tumor * No prior anti-HER2 monoclonal antibody preparation * No other concurrent immunotherapy * Recovered from prior chemotherapy * Multiple prior chemotherapy regimens allowed * No more than 320 mg/m\^2 total dose of prior doxorubicin allowed (including doxorubicin HCl liposome or other liposomally encapsulated doxorubicin preparations) * No concurrent chemotherapy * At least 1 week since prior hormonal therapy directed at the malignant tumor * No concurrent hormonal therapy * Continuation of hormone replacement therapy allowed * See Disease Characteristics * At least 3 weeks since prior radiotherapy for the malignant tumor and recovered * No concurrent radiotherapy * Recovered from prior recent surgery * At least 3 weeks since any prior therapy directed at the malignant tumor * No prior cancer treatment that would contraindicate study therapy